CrystalsFirst is thrilled to announce its joining of the PROXIDRUGS consortium, a groundbreaking initiative focused on developing innovative proximity-inducing drugs to target disease-causing proteins.
By joining PROXIDRUGS, CrystalsFirst aligns itself with a visionary project that spans the entire preclinical drug development pipeline. This collaboration promises to accelerate the translation of cutting-edge research into tangible therapeutic solutions, potentially transforming patient outcomes across multiple disease areas.
PROXIDRUGS is at the forefront of a revolutionary approach to drug discovery. This consortium brings together leading experts to create better therapies for a wide range of diseases, including cancer, inflammatory disorders, infectious diseases, and neurodegenerative conditions.
The core of PROXIDRUGS’ strategy lies in proximity-based pharmaceuticals, a novel class of drugs with the potential to degrade approximately 80% of disease-relevant proteins. This approach opens up new possibilities for treating conditions that have long eluded effective therapies.
We look forward to contributing our expertise to this consortium and working alongside academic and industry partners to push the boundaries of drug discovery. Together, we aim to unlock new paradigms in personalized medicine and address critical unmet medical needs.